FluMist, which was initially approved in 2023, is indicated for individuals from two to 49 years old. Those who want to ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

The FluMist vaccine, manufactured by AstraZeneca, had previously been approved back in 2003 to be given by health care ...

1 Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: “The approval of FLUMIST for self-administration is an important step forward in making vaccines more ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

FluMist, the nasal flu vaccine spray, was approved in September by the U.S. Food and Drug Administration for at-home use starting in fall 2025. Currently, it can only be administered by a healthcare ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN) has received approval from the US Food and Drug Administration (FDA) for its FluMist influenza vaccine to be self-administered, marking a significant shift in ...

Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

AstraZeneca disclosed Wednesday that Leon Wang, a high-ranking executive who oversees international operations and is also president of its subsidiary in China, is under investigation by Chinese ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...